MedTrace Logo

A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments

NCT04418765 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 892

Last updated 2023-09-29

Study results available
· View outcomes & findings →

Summary

Evaluation of eptinezumab in the prevention of migraine in participants with unsuccessful prior preventive treatments.

Conditions

Interventions

DRUG

Eptinezumab

Eptinezumab, concentrate for solution for infusion 100 mg/milliliter (mL)

DRUG

Placebo

concentrate for solution for infusion, intravenously

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-07-15
Completion
2022-09-15
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Bulgaria
  • Czechia
  • Denmark
  • Finland
  • France
  • Georgia
  • Germany
  • Hungary
  • Italy
  • Poland
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04418765 on ClinicalTrials.gov